Filing Details
- Accession Number:
- 0001179110-10-014047
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-09-20 17:22:54
- Reporting Period:
- 2010-09-16
- Filing Date:
- 2010-09-20
- Accepted Time:
- 2010-09-20 17:22:54
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1235010 | Momenta Pharmaceuticals Inc | MNTA | Biological Products, (No Disgnostic Substances) (2836) | 043561634 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1294284 | Ganesh Venkataraman | C/O Momenta Pharmaceuticals, Inc. 675 West Kendall Street Cambridge MA 02142 | Senior V.p., Research | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2010-09-16 | 11,100 | $15.07 | 330,605 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-09-17 | 3,900 | $15.02 | 326,705 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 25,2009.
- This transaction was executed in multiple trades at prices ranging from $15.00 to $15.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $14.81 to $15.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Billionaire Hedge Funds
